From Citizendium, the Citizens' Compendium
Jump to: navigation, search
This article is a stub and thus not approved.
Main Article
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
This editable Main Article is under development and not meant to be cited; by editing it you can help to improve it towards a future approved, citable version. These unapproved articles are subject to a disclaimer.
Tenofovir structure.jpg
IUPAC name: see chemistry section
Synonyms: TDF, PMPA
Formula: C9H14N5O4P

 Uses: HIV/AIDS & Hep. B

 Properties: RT inhibitor, adenosine analog

 Hazards: see drug interactions

Mass (g/mol): CAS #:
287.2123 147127-20-6

Tenofovir is a nucleotide analog reverse transcritase inhibitor (nRTI) antiviral drug used to treat HIV/AIDS and is in clinical trials for treatment of hepatitis B infection. The triphosphate from of the drug competes with the natural DNA nucleotide deoxyadenosine triphosphate (dATP) during DNA formation and it acts as a DNA chain terminator once incorporated because it lacks the normal deoxyribose sugar needed for connecting to the next DNA base.


The IUPAC chemical name for tenofovir is [(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonic acid and it has chemical formula C9H14N5O4P, giving it a molecular mass of 287.2123 g/mol. It is chemically similar to the natural neucleotide adenosine but lacks a ribose sugar unit.

Synonyms and brand names


  • Tenofovir disoproxil
  • Tenofovir disoproxil fumarate
  • D,L-Tenofovir
  • TDF
  • PMPA

Brand Names

  • Apropovir
  • Viread


Viread brand of tenofovir was approved for Gilead Sciences by the Food and Drug Administration in the United States with a New Drug Application (NDA) in 2001.[1]

A generic version with a AB Therapeutic Equivalence Code was approved for Cipla Limited with a Abbreviated New Drug Application (ANDA) in 2009.[2] The generic ANDA was reviewed under the expedited review provisions of the President’s Emergency Plan for AIDS Relief (PEPFAR) with the agreement that the drug would not be marketed in the United States until the Viread patent protection expires in 2017.


  1. Anonymous. Drugs@FDA for FDA Application No. 021356. U S Food and Drug Administration
  2. Anonymous. Drugs@FDA for FDA Application No. 078800. U S Food and Drug Administration

External links

The most up-to-date information about Tenofovir and other drugs can be found at the following sites.